Holen Sie sich die Stockscreener-App
11.73
0.86%
0.10
Handel nachbörslich:
11.73
Schlusskurs vom Vortag:
$11.63
Offen:
$11.21
24-Stunden-Volumen:
4.96M
Relative Volume:
2.39
Marktkapitalisierung:
$1.05B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$-74.42M
KGV:
-12.48
EPS:
-0.94
Netto-Cashflow:
$150.93M
1W Leistung:
+9.52%
1M Leistung:
+54.95%
6M Leistung:
+2.09%
1J Leistung:
-39.06%
1-Tages-Spanne:
$10.89
$11.73
1-Wochen-Bereich:
$10.54
$11.73
52-Wochen-Spanne:
$7.06
$33.48
Evolent Health Inc Stock (EVH) Company Profile
Firmenname
Evolent Health Inc
Sektor
Branche
Telefon
571-389-6000
Adresse
1812 NORTH MOORE ST, SUITE 1705, ARLINGTON
Vergleichen Sie EVH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EVH
Evolent Health Inc
|
11.73 | 1.05B | 2.35B | -74.42M | 150.93M | -0.94 |
|
VEEV
Veeva Systems Inc
|
282.61 | 46.43B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
59.18 | 12.01B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
59.31 | 10.79B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
101.28 | 9.27B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
38.67 | 7.03B | 906.14M | -52.62M | 89.62M | -0.3621 |
Evolent Health Inc Stock (EVH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Eingeleitet | Needham | Buy |
| 2024-12-03 | Bestätigt | BTIG Research | Buy |
| 2024-11-08 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2024-10-11 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2024-08-09 | Hochstufung | Truist | Hold → Buy |
| 2024-04-22 | Eingeleitet | Citigroup | Buy |
| 2024-03-01 | Eingeleitet | Oppenheimer | Outperform |
| 2024-01-03 | Eingeleitet | Barclays | Overweight |
| 2023-12-06 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-10-16 | Eingeleitet | UBS | Buy |
| 2023-04-12 | Eingeleitet | Stephens | Overweight |
| 2022-11-01 | Eingeleitet | Truist | Hold |
| 2022-07-29 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-03-30 | Eingeleitet | Guggenheim | Buy |
| 2021-11-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-04-29 | Fortgesetzt | JP Morgan | Neutral |
| 2021-01-07 | Eingeleitet | BTIG Research | Buy |
| 2020-07-06 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2020-06-05 | Herabstufung | Goldman | Buy → Neutral |
| 2020-06-02 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2018-10-05 | Fortgesetzt | Leerink Partners | Outperform |
| 2018-06-04 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-04-24 | Fortgesetzt | JP Morgan | Neutral |
| 2017-09-20 | Eingeleitet | KeyBanc Capital Mkts | Overweight |
| 2017-06-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2017-03-14 | Eingeleitet | Oppenheimer | Outperform |
| 2017-01-13 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2016-10-28 | Fortgesetzt | JP Morgan | Overweight |
| 2016-08-05 | Bestätigt | FBR Capital | Outperform |
| 2016-07-26 | Eingeleitet | Jefferies | Buy |
| 2016-07-13 | Bestätigt | FBR Capital | Outperform |
| 2016-03-29 | Eingeleitet | FBR Capital | Outperform |
| 2016-01-06 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-06-30 | Eingeleitet | Goldman | Buy |
| 2015-06-30 | Eingeleitet | JP Morgan | Overweight |
| 2015-06-30 | Eingeleitet | Leerink Partners | Outperform |
| 2015-06-30 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
Alle ansehen
Evolent Health Inc Aktie (EVH) Neueste Nachrichten
EVH Q1 Earnings Call: Oncology Navigation Launch and AI Automation Drive Strategic Focus - Yahoo Finance
Evolent Health, Inc. Appoints Shawn Guertin to the Board of Directors and Reconstitutes Compositions of Committees, Effective June 5, 2025 - marketscreener.com
3 Stocks Under $10 in the Doghouse - Yahoo Finance
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Evolent Health, Inc. To Contact The Firm - ACCESS Newswire
Evolent Health at William Blair Conference: Strategic Growth Amid Challenges - Investing.com Australia
Evolent Health Reaffirms 2025 Revenue and EBITDA Guidance - TipRanks
Evolent HealthReaffirms 2025 Revenue Guidance Of $2.06 Bln To $2.11 BlnSEC Filing - marketscreener.com
Why Investors Shouldn't Be Surprised By Evolent Health, Inc.'s (NYSE:EVH) 25% Share Price Plunge - simplywall.st
Evolent Health, Amphastar Pharmaceuticals, Iridium, and Magnite Stocks Trade Up, What You Need To Know - Yahoo Finance
Evolent Health’s SWOT analysis: value-based care provider faces challenges, opportunities - Investing.com Australia
Evolent Health’s SWOT analysis: value-based care provider faces challenges, opportunities By Investing.com - Investing.com South Africa
Evolent Health, Inc. (NYSE:EVH) Given Average Recommendation of “Buy” by Analysts - Defense World
Deutsche Bank AG Raises Holdings in Evolent Health, Inc. (NYSE:EVH) - Defense World
Trend Tracker for (EVH) - news.stocktradersdaily.com
Reflecting On Healthcare Technology for Providers Stocks’ Q1 Earnings: Evolent Health (NYSE:EVH) - Yahoo Finance
Evolent Health stock hits 52-week low at $8.35 By Investing.com - Investing.com South Africa
Guardant Health, Evolent Health, Charles River Laboratories, Avantor, and Lumen Stocks Trade Down, What You Need To Know - Yahoo Finance
Evolent Health stock hits 52-week low at $8.35 - Investing.com Australia
Comerica Bank Has $69,000 Holdings in Evolent Health, Inc. (NYSE:EVH) - Defense World
Needham & Company LLC Reiterates Buy Rating for Evolent Health (NYSE:EVH) - Defense World
Evolent Health (EVH) Sees Analyst Reaffirm Buy Rating and $15 Pr - GuruFocus
Evolent Health (EVH) Sees Analyst Reaffirm Buy Rating and $15 Price Target | EVH Stock News - GuruFocus
Evolent Health (NYSE:EVH) Price Target Raised to $15.00 - Defense World
Evolent Health (NYSE:EVH shareholders incur further losses as stock declines 15% this week, taking three-year losses to 68% - simplywall.st
Evolent Health (EVH) Receives Price Target Upgrade from UBS | EV - GuruFocus
Evolent Health, Inc. (NYSE:EVH) Q1 2025 Earnings Call Transcript - Insider Monkey
Analysts Have Conflicting Sentiments on These Healthcare Companies: Evolent Health (EVH), Verastem (VSTM) and Sight Sciences (SGHT) - The Globe and Mail
Evolent Health Inc. Earnings Call Highlights Growth and Expansion - TipRanks
Expert Outlook: Evolent Health Through The Eyes Of 9 Analysts - Benzinga
Evolent Health (EVH) Receives Price Target Upgrade from UBS | EVH Stock News - GuruFocus
Evolent Health (EVH) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Evolent Health Q1 2025 slides: Revenue falls but company maintains full-year guidance - Investing.com Australia
UBS Adjusts Price Target on Evolent Health to $15 From $14, Maintains Buy Rating - marketscreener.com
Evolent Health (EVH) Receives Price Target Boost from UBS | EVH Stock News - GuruFocus
Evolent Health Surpasses Revenue Expectations Despite Sales Decline - IndexBox
Evolent Health Inc earnings missed by $0.02, revenue topped estimates - Investing.com India
Evolent Health, Inc. SEC 10-Q Report - TradingView
Evolent Health Inc (EVH) Q1 2025 Earnings Call Highlights: Strong Start with New Agreements and ... By GuruFocus - Investing.com Canada
Evolent Health Inc (EVH) Q1 2025 Earnings Call Highlights: Strong Start with New Agreements and ... - Yahoo Finance
Evolent Health Inc (EVH) Q1 2025 Earnings Call Highlights: Strong Start with New Agreements and AI Advancements - GuruFocus
Earnings call transcript: Evolent Health Q1 2025 misses EPS forecast, stock rises - Investing.com
Evolent Health: Q1 Earnings Snapshot - Norwalk Hour
Evolent Health Reports Strong Q1 2025 Growth - TipRanks
Evolent Health Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Evolent Health (EVH) Q1 Earnings Lag Estimates - Yahoo Finance
Evolent Health (NYSE:EVH) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations - Yahoo Finance
Finanzdaten der Evolent Health Inc-Aktie (EVH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Evolent Health Inc-Aktie (EVH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| McCarthy Daniel Joseph | PRESIDENT |
Mar 06 '25 |
Buy |
9.01 |
11,040 |
99,470 |
389,004 |
| Jelinek Richard M | Director |
Mar 07 '25 |
Buy |
9.12 |
30,000 |
273,750 |
15,000 |
| GRUA PETER J | Director |
Mar 06 '25 |
Buy |
9.01 |
11,040 |
99,470 |
18,749 |
| Blackley Seth | Chief Executive Officer |
Mar 06 '25 |
Buy |
9.01 |
55,225 |
497,577 |
762,217 |
| Springstubb Brendan B | Director |
Mar 07 '25 |
Buy |
9.27 |
15,000 |
139,050 |
26,842 |
| Glass Russell Monroe | Director |
Mar 06 '25 |
Buy |
9.27 |
5,400 |
50,058 |
14,272 |
| KECK KIM | Director |
Mar 07 '25 |
Buy |
9.44 |
10,540 |
99,498 |
39,522 |
| Barbarosh Craig A. | Director |
Mar 06 '25 |
Buy |
8.81 |
2,000 |
17,620 |
31,956 |
| Springstubb Brendan B | Director |
Mar 04 '25 |
Buy |
8.75 |
5,000 |
43,750 |
11,842 |
1.70%
0.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):